CA
BNTC icon

Clearstead Advisors’s Benitec Biopharma BNTC Stock Holding History

Clearstead Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54 Buy
+4
New +$47 ﹤0.01% 3469

Other funds holding BNTC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Clearstead Advisors's BNTC Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Benitec Biopharma (BNTC) in Q2 2026: 4 shares worth $54. The stake represents ﹤0.01% of the portfolio and ranks #3469 among its holdings.

23 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Clearstead Advisors held 4 shares of Benitec Biopharma worth $54 as of Q2 2026.
  • Benitec Biopharma was a new Clearstead Advisors position in Q2 2026.
  • Benitec Biopharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3469 holding.
  • 23 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.